



## PRESS RELEASE

## ANNIVERSARY EDITION OF CACLP AND CISCE TO EMPOWER FUTURE DEVELOPMENT OF THE IVD INDUSTRY

The 20th edition of China Association of Clinical Laboratory Practice Expo (CACLP) and the 3rd edition of China IVD Supply Chain Expo (CISCE) will return to the Nanchang Greenland International Expo Center 28-30 May 2023.



CACLP will celebrate its 20th anniversary next year together, along with the 3rd CISCE, with the number of exhibitors expected to rise by 15% to over 1600 and the exhibiting space reaching over 130,000 sqm in Nanchang, China.

CACLP originally started as a IVD supply chain event and has grown up to an industrial platform covering both trade show and academic programs for over hundreds and thousands of professionals from around the globe. The event is becoming 'the place to be' for showcasing the latest trends and exchanging the most advanced knowledge from the IVD and laboratory medicine fields domestically and internationally.

Professor Haibo SONG, the chairman of CAIVD (China Association of In-Vitro diagnostics) and the founder of CACLP, comments, "In the past two decades, we have been in over 10 different destinations together with the IVD industry players and experts and witness the transformation of the industry from small to large, and from immature to strong. That will be our great honor to celebrate the 20th anniversary all together next year in Nanchang."







In vitro diagnostics is one of the most active and fastest-growing fields in the medical market in recent years and has gradually formed a large-scale mature industry worldwide. In 2021, the global in vitro diagnostic market size was valued at USD 111.67 billion and is projected to grow at a compound annual growth rate (CAGR) of 0.2% from 2022 to 2030. Meanwhile, the Chinese IVD market size reached USD 15 billion in 2021, accounting for about 14.43% of the global market. It is expected to be worth USD 40 billion by 2030, becoming the largest consumer of in vitro diagnostic products.

In 2016, the Chinese government released the Healthy China 2023 initiative, outlining 13 core indicators to be reported in 2020 and 2030. According to the blueprint, the investment capital for the construction of the health service industry is planned to exceed CNY 1.6 trillion in 2030. Additionally, China released its first five-year plan on bioeconomy on 10<sup>th</sup> May 2022. The plan clearly states the goal of making bioeconomy a strong driving force for quality development. From 2021 to 2025, the government will support innovation in life science and biotechnology, particularly the advancements in next generation sequencing, microfluidic technologies, and high-sensitivity diagnostic technologies. The construction of international bio-industrial parks will be accelerated at the same time to promote international cooperation in the field of health care according to the public news.

The developments of 'Healthy China' and bioeconomy are central to the Chinese medical and health industry – and has the potential to reap huge benefits for the rest of the world. CACLP & CISCE will play an indispensable role in leading technological innovation to create the highest-quality business community, supporting the 'Healthy China' initiative and serving the further development of bioeconomy.





In 2023, CACLP & CISCE will showcase advanced technologies and developments in 14 product sectors: biochemical diagnosis, immunodiagnostics, molecular diagnosis, blood & body fluids diagnosis, point of care, biological raw materials, components, consumables, laboratory equipment, cold-chain logistics, packaging & filling equipment, manufacturing & design and contract research service.

Moreover, over 20 academic conferences and forums will take place at the convention centre next to Nanchang Greenland International Expo Center 26-29 May 2023, welcoming an anticipated 5,000+ delegates. 300+ speakers have been officially invited to share their knowledge and opinions around pathology, clinical laboratory, product registration, quality management, microbiology, blood transfusion, mass spectrometry, tumour screening, molecular diagnostics, and other popular topics.



We believe that the 20th anniversary will be the start of our new journey, shaping the platform from 'in China for China' to 'in China for the world' and empowering the development of the IVD industry at home and abroad.

For more information, please visit: <a href="https://en.caclp.com">https://en.caclp.com</a>



## **About GL events**

GL events, whose HQ is located in Lyon, was founded in 1978. It is listed on Euronext Paris, Segment B. The core business of GL events covers three business segments, i.e. VENUES (venue management), EXHIBITIONS (exhibition organization) and LIVE (consulting, design and services for events). Through its wide global network of more than 90 offices, with 483 proprietary exhibitions and events, managing 60+ venues and serving 4,200 events, GL events is a critical force for the city promotion of 28 MICE destinations. GL events reported consolidated annual revenue of over €1.1 billion for 2019, which ranked a leading position in the industry.

## **About CACLP**

CACLP is committed to building a large platform of production, learning, research, application, education, management, and service, which integrates academic exchange, industry forum, sharing innovations, and the exhibition. CACLP has always followed the belief and tenet of serving the IVD industry sincerely, promoting the continuous progress of the IVD industry, promoting the communication and cooperation within the IVD industry, improving the cooperation with the international IVD industry, and establishing equal communication and cooperation with laboratory medicine experts, experimental medicine experts and IVD entrepreneurs.

Contact for press: Tiki WANG tiki.wang@gl-events.com Tel: +86 21 5255 8215